

Efficient and Selective Syntheses of *S*-Acyl and *N*-Acyl Glutathiones

Alan R. Katritzky,^{*a} Nader E. Abo-Dya,^{a,b} Srinivasa R. Tala,^a Ebrahim H. Ghazvini-Zadeh,^a Kiran Bajaj,^a Said A. El-Feky^b

^a Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, FL 32611-7200, USA
Fax +1(352)3929199; E-mail: katritzky@chem.ufl.edu

^b Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt

Received 8 February 2010

Abstract: Selective syntheses of *S*-acyl glutathiones are achieved in 79–98% yields using 1-acyl-1*H*-benzotriazoles in the presence of potassium bicarbonate in aqueous methanol at 20 °C. *N*-Acylation of *S*-(*p*-nitrobenzoyl) glutathione with 1-acyl-1*H*-benzotriazoles followed by deprotection of the *p*-nitrobenzoyl groups under mild conditions gave 63–78% yields of *N*-acyl glutathiones. These methodologies should be useful for the *S*-acylation and *N*-acylation of peptides and glycopeptides.

Key words: amino acids, acylation, glutathione, peptides, drugs

Glutathione (γ -L-glutamyl-L-cysteinylglycine, GSH, **1**), a tripeptide derived from glycine, cysteine, and glutamic acid, is critical to a variety of cellular functions.¹ GSH, which possesses a γ -glutamyl linkage and a sulfhydryl group as two characteristic structural features, plays an important role in the human body antioxidant defense system. In its reduced form, GSH (**1**) is the most abundant nonprotein thiol in eukaryotic cells, and is involved in various physiological and metabolic functions of all mammalian cells.² The *N*- and *S*-blocked GSH derivatives inhibit mammalian glyoxalase I from human erythrocytes.³

S-Acetyl glutathione can act as selective apoptosis-inducing agent in cancer therapy⁴ and as an antiviral agent against herpes simplex virus-1 infection.⁵ *S*-Acetyl glutathione is also a potent antioxidant, providing a rationale for its combination with antiretroviral drugs.⁶

The hepatotoxic nonsteroidal anti-inflammatory drug Zomepirac, containing a carboxylic acid group, undergoes metabolic activation in vivo in rats, and in vitro in rat hepatocytes, to form unstable acyl-linked metabolites that react with GSH by transacylation forming the *S*-acyl glutathione conjugate of the drug. Therefore, the detection of *S*-acyl-linked GSH adducts of carboxylic acid drugs can be used as an indirect marker of drug bioactivation to chemically reactive transacylating metabolites.⁷


N-(4-Benzoylbenzoyl) glutathione is a photoaffinity label of glutathione *S*-transferases.² *N*-Acyl glutathiones bearing an aryl azide moiety provide photoactivatable analogues of GSH.⁸

Several literature reports of the selective *S*-acylation of GSH utilize (a) coupling reagents such as ethyl chloro-

formate–Et₃N⁹ (b) reactions of GSH with acyl chlorides or anhydrides in trifluoroacetic acid,¹⁰ and (c) use of enzyme.¹¹


Published methods to synthesize *N*-acyl glutathiones have utilized (a) potassium phosphate buffer, which provided a mixture of *N*- and *S*-acylated products;¹² (b) an activated ester,¹³ but Bernardi et al. observed only *S*-acylation of GSH using these conditions;² (c) *N*-acylation of GSSG with activated ester followed by reduction,^{2,8,14} but this method fails when other susceptible groups like azide present in the molecule during the reduction;⁸ (d) use of trityl group to protect thiol group of GSH then *N*-acylation followed by trityl group deprotection,⁸ but overall yields are very low. Some of these methods also suffer from long reactions times (48 h).^{2,8,14}

Recently, we have reported selective syntheses of *S*-acyl- and *N*-acylcysteines (Scheme 1).¹⁵ However, our attempts to synthesize *S*-acyl glutathiones according to the above method for *S*-acylation of cysteine¹⁵ failed to proceed after several days. Furthermore, treatment of GSH with *N*-acylbenzotriazoles in the presence of triethylamine did not yield *N*-acyl glutathiones, according to the method used for *N*-acylcysteines.¹⁵ Use of excess of triethylamine gave low yields of *S*,*N*-diacylated product. Hence, the methods successful for the selective syntheses of *S*-acyl- and *N*-acylcysteines can not be used for selective synthesis of *S*-acyl and *N*-acyl glutathiones.



Scheme 1 Selective synthesis of *S*-acyl and *N*-acylcysteines

We now report facile, mild, and efficient syntheses of *S*-acyl and *N*-acyl glutathiones, which should have general applicability for *S*-acylation and *N*-acylation of biologically important larger peptides and glycopeptides. 1-Acyl-1*H*-benzotriazoles are stable crystalline compounds and advantageous for *N*-, *O*-, *C*-, and *S*-acylation.^{16a–j}


**Scheme 2** Synthesis of *S*-acyl glutathiones **3a–g****Table 1** Preparation of *S*-Acyl Glutathiones **3a–g**

RCOBt 2	Product	Yield (%)	Mp (°C)
Fmoc-Val-Bt 2a	3a	79	165–167
naproxen-Bt 2b	3b	89	204–205
4-MeOC ₆ H ₄ COBt 2c	3c	95	222–224
4-MeC ₆ H ₄ COBt 2d	3d	97	228–230
2-naphthylCOBt 2e	3e	98	233–235
4-O ₂ NC ₆ H ₄ COBt 2f	3f	91	203–205
Cbz-Ala-Bt 2g	3g	94	184–185

Treatment of GSH (**1**) with one equivalent of 1-acyl-1*H*-benzotriazoles **2a–g** in the presence of one equivalent of potassium bicarbonate at 20 °C in aqueous methanol for 15 minutes gave exclusively *S*-acyl glutathiones **3a–g** in 79–98% yields as the only products isolated (Scheme 2, Table 1). Of the two carboxylic acid groups present in the GSH, one forms a zwitterion with the amino group, but the other is free; we used potassium bicarbonate to neutralize it and then selectively *S*-acylated GSH.

Reaction of GSH (**1**) with two equivalents of 1-acyl-1*H*-benzotriazole **2c** in the presence of triethylamine at 20 °C in 1.5 hours gave the *S,N*-diacylation product **4** in 75% yield (Scheme 3).

In GSH, an anionic thiol group is more nucleophilic than an amino group, thus for selective *N*-acylation of GSH, we first protected thiol group of **1** with a 4-nitrobenzoyl

**Scheme 3** Synthesis of bisacyl glutathione **4****Table 2** Preparation of *S,N*-Diacyl Glutathiones **5a–e** and *N*-Acyl Glutathiones **6a–e**

RCOBt 2	Yield (%) of 5	Mp (°C)	Yield (%) of 6	Mp (°C)
Cbz-Ala-Bt 2g	5a , 84	132–134	6a , 65	182–183
Cbz-Phe-Bt 2h	5b , 82	162–163	6b , 65	203–204
Cbz-Leu-Bt 2i	5c , 89	150–152	6c , 78	198–200
4-O ₂ NC ₆ H ₄ COBt 2f	5d , 80	140–141	6d , 80	210–212
Fmoc-Val-Bt 2a	5e , 84	183–184	6e , 63	174–175


group. 4-Nitrobenzoyl is a known protecting group for thiols.¹⁷ *S*-(4-Nitrobenzoyl) glutathione (**3f**) was synthesized by *S*-acylation of GSH (**1**, Scheme 2), **3f** was used as an intermediate to make *N*-acyl glutathiones **6a–e**. *S*-(4-Nitrobenzoyl) glutathione (**3f**) was acylated with one equivalent of each of various 1-acyl-1*H*-benzotriazoles **2a,f–i** in the presence of one equivalent of triethylamine in aqueous acetonitrile for 1.5 hours to afford the corresponding *S,N* doubly acylated GSH derivatives **5a–e**, in 80–89% yields. Mild deprotection of the 4-nitrobenzoyl groups from these double acylated glutathione derivatives **5a–e** using pyrrolidine in dry THF–methanol for four hours at room temperature, gave the corresponding *N*-acyl glutathiones **6a–e** in 63–80% yields (Scheme 4, Table 2).

In conclusion, we have developed facile and efficient methods for selective syntheses for both *S*-acyl glutathiones¹⁸ and *N*-acyl glutathiones^{19,20} in good yields under mild reaction conditions using 1-acyl-1*H*-benzotriazoles. In comparison with literature methods, our methods comprise: (1) mild and simple reaction and workup conditions, (2) higher yields for the most of our products (65–98%), and (3) reduced reaction times (15 min to 6 h). These methodologies should have general applicability for the *S*-acylation and *N*-acylation of biologically active larger peptides and glycopeptides.

Supporting Information for this article is available online at <http://www.thieme-connect.com/ejournals/toc/synlett>.

Acknowledgment

We thank Dr. C. D. Hall for helpful discussions.



Scheme 4 Synthesis of *N*-acyl glutathiones **6a-e**

References and Notes

- (1) Pompella, A.; Visvikis, A.; Paolicchi, A.; Tata, V. D.; Casini, A. F. *Biochem. Pharmacol.* **2003**, *66*, 1499.
- (2) Bernardi, D.; Battaglia, E.; Krisch, G. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1601.
- (3) Al-Timari, A.; Douglas, K. T. *Biochim. Biophys. Acta* **1986**, *870*, 160.
- (4) Donnerstag, B.; Ohlenschläger, G.; Cinatl, J.; Amrani, M.; Hofmann, D.; Flindt, S.; Treusch, G.; Träger, L. *Cancer Lett.* **1996**, *110*, 63.
- (5) Vogel, J.-U.; Cinatl, J.; Dauletbaev, N.; Buxbaum, S.; Treusch, G.; Cinatl, J. Jr.; Gerein, V.; Doerr, H. W. *Med. Microbiol. Immunol.* **2005**, *194*, 55.
- (6) Fraternali, A.; Paoletti, M. F.; Casabianca, A.; Orlandi, C.; Schiavano, G. F.; Chiarantini, L.; Clayette, P.; Oiry, J.; Vogel, J.-U.; Cinatl, J. Jr.; Magnani, M. *Antiviral Res.* **2008**, *77*, 120.
- (7) Grillo, M. P.; Hua, F. *Drug Metab. Dispos.* **2003**, *31*, 1429.
- (8) Bernardi, D.; Ba, L. A.; Kirsch, G. *Synthesis* **2007**, 140.
- (9) Stadtman, E. R. *Methods Enzymol.* **1957**, *3*, 931.
- (10) Galzigna, L. WO 9200320, **1992**.
- (11) Clelland, J. D.; Thornalley, P. J. *J. Chem. Soc., Perkin Trans. I* **1991**, 3009.
- (12) Chen, H.-J. C.; Hsieh, C.-J.; Shen, L.-C.; Chang, C.-M. *Biochemistry* **2007**, *46*, 3952.
- (13) Karwatsky, J.; Daoud, R.; Cai, J.; Gros, P.; Georges, E. *Biochemistry* **2003**, *42*, 3286.
- (14) Kiwada, H.; Akimoto, M.; Araki, M.; Tsuji, M.; Kato, Y. JP 63002922, **1988**.
- (15) Katritzky, A. R.; Tala, S. R.; Abo-Dya, N.; Gyanda, K.; El-Gendy, B. E.; Abdel-Sammi, Z. K.; Steel, P. J. *J. Org. Chem.* **2009**, *74*, 7165.
- (16) (a) Katritzky, A. R.; Suzuki, K.; Wang, Z. *Synlett* **2005**, 1656. (b) Katritzky, A. R.; Angrish, P.; Suzuki, K. *Synthesis* **2006**, 411. (c) Katritzky, A. R.; Angrish, P.; Hür, D.; Suzuki, K. *Synthesis* **2005**, 397. (d) Katritzky, A. R.; Suzuki, K.; Singh, S. K.; He, H.-Y. *J. Org. Chem.* **2003**, *68*, 5720. (e) Katritzky, A. R.; He, H.-Y.; Suzuki, K. *J. Org. Chem.* **2000**, *65*, 8210. (f) Katritzky, A. R.; Wang, M.; Yang, H.; Zhang, S.; Akhmedov, N. G. *ARKIVOC* **2002**, (viii), 134. (g) Katritzky, A. R.; Shestopalov, A. A.; Suzuki, K. *ARKIVOC* **2005**, (vii), 36. (h) Katritzky, A. R.; Tala, S. R.; Singh, S. K. *Synthesis* **2006**, 3231. (i) Katritzky, A. R.; Chen, Q.-Y.; Tala, S. R. *Org. Biomol. Chem.* **2008**, *6*, 2400. (j) Katritzky, A. R.; Angrish, P.; Todadze, E. *Synlett* **2009**, 2392.
- (17) Ané, A.; Josse, S.; Naud, S.; Lacône, V.; Vidot, S.; Fournial, A.; Kar, A.; Pipelier, M.; Dubreuil, D. *Tetrahedron* **2006**, *62*, 4784.
- (18) **General Procedure for the Preparation of Compounds 3a-e**
To a solution of GSH (1 equiv) in H_2O (3 mL), a solution of 1-acyl-1*H*-benzotriazole (1 equiv) in MeOH (8 mL) was added, and the mixture was stirred for 5 min at r.t. An aq KHCO_3 solution (2 equiv) in H_2O (1 mL) was added dropwise to the reaction mixture at a rate of 0.2 mL/min. The reaction progress was monitored by TLC (disappearance of 1-acyl-1*H*-benzotriazoles, which have R_f values in the range from 0.6–0.7 using solvent mixture of hexanes–EtOAc (2:1) as eluent; together with the appearance of benzotriazole at R_f value 0.45), which indicated the completion of the reaction within 10–15 min. MeOH was evaporated under reduced pressure and dilute HCl (6 M)/ Na_2HPO_4 (1 N) was added until pH of the mixture was adjusted to 5. The precipitate formed was collected on a Buchner funnel, was washed with H_2O , EtOAc, and hexanes to afford the desired compound.
- (19) **General Procedure for the Preparation of Compounds 5a-e**
A solution of 1-acyl-1*H*-benzotriazole (1 equiv) in MeCN (5 mL) and Et_3N (2 equiv) was added to a solution of **3f** (1 equiv) in MeCN– H_2O (1 mL – 2 drops). The reaction mixture was stirred at r.t. for 1.5 h. After completion of the reaction (by TLC as described above for compounds **3a-e**), the pH was adjusted to 3 using HCl (6 M). MeCN was evaporated under reduced pressure, and the resulting crude was triturated with Et_2O (5 mL) until a friable solid was formed. The solid was filtered and washed with additional

amount of Et₂O (2 mL) and dried to give the desired compound.

(20) **General Procedure for the Preparation of Compounds 6a–e**

Pyrrolidine (3 equiv) was added to a stirred solution of **5a–e** (1 equiv) in anhyd THF and MeOH (3:1, 4 mL). The mixture

was stirred at 20 °C for 4 h. The solvents were then evaporated, and the resulting crude solid was dissolved in H₂O (2 mL) and MeOH (0.2 mL). The resulting solution was acidified to pH 1 using HCl (6 M) and stirred for 30 min. The precipitate was filtered and washed with Et₂O to afford the desired product.

Copyright of Synlett is the property of Georg Thieme Verlag Stuttgart and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.